NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Enveric Biosciences, Inc. ENVB
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-36.24
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-304.0%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 16-year series below
Revenue
Net income
Per share
USD -36.24
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-304.0%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-214.5%
Each USD of equity lost 304 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+3.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years+49.6%
Change, 10 years—
The share count grew 50% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 5.1M
total assets, end of FY2025
Total assetsUSD 5.1M
EquityUSD 4.2M
Current ratio5.38×
Equity funds 82% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
·
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.1
·
·
·
·
−0.0
−0.0
·
·
·
·
·
Income tax $B
·
0.0
0.0
−0.0
−0.0
·
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−36.24
−228.48
−121.29
−13.00
−2.07
−1.19
−0.46
−20.47
−0.75
−0.21
−0.07
0.00
0.00
0.00
0.00
−0.01
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−304.0
−539.6
−208.0
−99.9
−380.8
−855.9
·
−174.4
−58.3
−46.6
−639.3
·
·
·
·
·
Shares out B
0.00
0.00
0.00
0.00
0.00
0.01
0.01
0.00
0.02
0.01
0.01
0.02
0.01
0.01
0.01
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed